News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. envoy urged Taiwan's legislature to approve a supplemental defense budget for U.S. systems and domestic weapons.
  • Chinese semiconductor stocks climbed on renewed AI demand, with SMIC up about 9% and foundry, packaging and equipment names rallying.
  • Global markets refocused on AI after hyperscaler spending signals and strong chip earnings, lifting Japan, South Korea and Taiwan to record highs.
  • Iran's deputy foreign minister flew to Moscow as U.S.-Iran talks stalled, and Strait of Hormuz disruptions pushed oil prices higher.
  • Goldman raised Q4 2026 Brent and WTI forecasts, citing weaker Middle East output and delayed normalization of Hormuz exports.
  • The U.S. and EU signed deals to deepen critical-minerals cooperation and explore trade measures to reduce processing concentration risks.
  • Toyota's global March sales fell 7.3% year-on-year as Middle East weakness and a RAV4 production changeover hit deliveries.

Latest Articles

GeneDx CFO Sells $557K in Shares as Analysts Hold Positive Views

GeneDx CFO Sells $557K in Shares as Analysts Hold Positive Views

GeneDx Holdings Corp CFO Kevin Feeley sold 7,718 Class A shares on March 26, 2026, generating about $557,051 in proceeds. The sales coincided with a 17% drop in the stock over the preceding week. Feeley also exercised restricted stock units the same day for 16,250 shares at no cost and now directly holds 34,580 shares. The company reported strong f…

Solas Capital Disposes of Epsilon Energy Stakes After Recent Rally

Solas Capital Disposes of Epsilon Energy Stakes After Recent Rally

Solas Capital Management, together with Frederick Tucker Golden, sold a combined 74,425 shares of Epsilon Energy Ltd. (NASDAQ: EPSN) between March 26 and March 30, 2026, generating proceeds of $462,333. The transactions took place in three tranches at prices between $6.17 and $6.25. The company’s stock trades at $6.36 and has risen 38.6% year-to-da…

SL Green Director Sells Entire Stake as Shares Trade Near 52-Week Low

SL Green Director Sells Entire Stake as Shares Trade Near 52-Week Low

Carol N. Brown, a director at SL Green Realty Corp. (NYSE: SLG), sold all 5,004 of her common shares on March 30, 2026, for $36.325 each, a transaction totaling $181,770, according to a Form 4 filed with the SEC. The sale leaves Brown with no holdings and occurs while SLG shares hover near their 52-week low of $34.77. The company recently reported …

General American Investors VP Increases Stake in 5.95% Preferred Stock

General American Investors VP Increases Stake in 5.95% Preferred Stock

Eugene S. Stark, General American Investors Co Inc's VP Administration/CCO/PFO, bought a combined 838 shares of the company's 5.95% Preferred Stock across two transactions on March 27 and March 30, 2026. The purchases totaled $20,902. After the trades, Stark's direct and indirect holdings in the preferred and common shares are detailed below. GAM's…

CME Group Director William R. Shepard Buys $437,101 of Stock

CME Group Director William R. Shepard Buys $437,101 of Stock

CME Group Director William R. Shepard purchased $437,101 worth of company stock on March 26, 2026, acquiring shares both directly and through a trust. The transactions occurred near the market price as the derivatives operator reports record open interest in U.S. Treasury products and moves to expand crypto trading hours.

Xilio Therapeutics Director Adds 5,000 Shares in March Transaction

Xilio Therapeutics Director Adds 5,000 Shares in March Transaction

Xilio Therapeutics director Shannon James Samuel purchased 5,000 shares of common stock on March 26, 2026, for a total of $43,949 at a reported price of $8.79 per share. The SEC filing notes transaction prices ranged from $8.6758 to $9.2499. After the purchase, Samuel directly owns 10,000 shares. The transaction occurs while XLO trades at $8.23 and…

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Pharmaceuticals reports significant progress in manufacturing, toxicology, intellectual property, and regulatory preparations for its lead drug candidate Phyto-N, targeting ulcerative colitis. The company completed GMP pilot batch production and pivotal toxicology studies, aiming for an IND submission by late 2026 and plans to initiate Phas…

Mexico Stocks Close Higher as Industrials and Consumer Names Lead Gains

Mexico Stocks Close Higher as Industrials and Consumer Names Lead Gains

Mexico's main equity index, the S&P/BMV IPC, finished the trading day up 0.60%, paced by strength in the Industrials, Consumer Goods & Services and Consumer Staples sectors. Leading individual gains included Industrias Peñoles, Grupo Carso and Grupo Bimbo, while airport operators posted the largest declines. Commodity markets saw crude oil climb an…

Colombian equities slide as COLCAP closes down 0.80%

Colombian equities slide as COLCAP closes down 0.80%

Colombian shares ended lower as the COLCAP index fell 0.80%, dragged by losses across Financials, Investment and Public Services. A few large-cap names posted gains, but major banks and service companies recorded some of the heaviest drops. Commodities and currency moves accompanied the trading day.

PepGen Shares Plunge After Phase 2 5 mg/kg Cohort Shows Minimal Benefit

PepGen Shares Plunge After Phase 2 5 mg/kg Cohort Shows Minimal Benefit

Shares of PepGen Ltd (NASDAQ:PEPG) plunged 44% in after-hours trading after the company disclosed Phase 2 FREEDOM2-DM1 data for the 5 mg/kg multiple ascending dose cohort. The treatment arm showed a mean splicing correction of 7.3% versus 6.8% for placebo, with six patients in the active group and two in placebo. Excluding one patient who experienc…